CVAC - CureVac adds 26% as analysts cheer mRNA based COVID and flu shots

• Following a ~29% gain in the previous session, German biotech CureVac N.V. ( NASDAQ: CVAC ) climbed another ~27% pre-market Monday as Wall Street welcomed the early Phase 1 data for the mRNA-based COVID-19 and flu shots the company develops with GSK ( GSK ).
• About ~445.7K CureVac ( CVAC ) shares have already changed hands compared to the 65-day average of ~453.5K.
• The readouts for vaccines, which the company said would support the next phase of their clinical studies in 2023 , have prompted Jefferies to upgrade CureVac ( CVAC ) to Buy from Hold, raising its price target to $21 from $6 per share.
• The analyst Eun Yang thinks the results prove the company’s mRNA platform technology validating its second-generation mRNA backbone.
• Meanwhile, highlighting the long-term potential of mRNA technology in prophylactic vaccines, UBS analyst Eliana Merle argues that the preliminary data release is a “key milestone” for the Tübingen-based company.
• In September, Seeking Alpha contributor Chetan Woodun urged investors “to wait for concrete news” before buying the shares of CureVac ( CVAC ). The analyst issued a Hold rating on the stock.

For further details see: